Comparison of Mortality and Morbidity in Patients With Atrial Fibrillation and Heart Failure With Preserved Versus Decreased Left Ventricular Ejection Fraction

被引:42
作者
Badheka, Apurva O. [1 ]
Rathod, Ankit [1 ]
Kizilbash, Mohammad A. [2 ]
Bhardwaj, Aditya [1 ]
Ali, Omaima [1 ]
Afonso, Luis [1 ,2 ]
Jacob, Sony [1 ,2 ]
机构
[1] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Div Cardiol Electrophysiol, Detroit, MI 48201 USA
关键词
PREDICTING STROKE; PROGNOSTIC-SIGNIFICANCE; CLINICAL EVENTS; RISK; READMISSION; SURVIVAL; DEATH;
D O I
10.1016/j.amjcard.2011.06.045
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Almost 50% of patients with congestive heart failure (HF) have preserved ejection fraction (PEF). Data on the effect of HF-PEF on atrial fibrillation outcomes are lacking. We assessed the prognostic significance of HF-PEF in an atrial fibrillation population compared to a systolic heart failure (SHF) population. A post hoc analysis of the National Heart, Lung, and Blood Institute-limited access data set of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial was carried out. The patients with a history of congestive HF and a preserved ejection fraction (EF >50%) were classified as having HF-PEF (n = 320). The patients with congestive HF and a qualitatively depressed EF (EF <50%) were classified as having SHF (n = 402). Cox proportional hazards analysis was performed. The mean follow-up duration was 1,181 +/- 534 days/patient. The patients with HF-PEF had lower all-cause mortality (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.46 to 0.85, p = 0.003) and cardiovascular mortality (HR 0.56, 95% CI 0.38 to 0.84, p = 0.006), with a possible decreased arrhythmic end point (HR 0.39, 95% CI 0.16 to 1.006, p = 0.052) than did the patients with SHF. No differences were observed for ischemic stroke (HR 1.08, 95% CI 0.48 to 2.39, p = 0.86), rehospitalization (HR 0.89, 95% CI 0.75 to 1.07, p = 0.24), or progression to New York Heart Association class III-IV (odds ratio 0.80,95% CI 0.42 to 1.54, p = 0.522). In conclusion, although patients with HF-PEF have better mortality outcomes than those with SHF, the morbidity appears to be similar. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:1283-1288)
引用
收藏
页码:1283 / 1288
页数:6
相关论文
共 29 条
  • [11] Pharmacotherapy of Atrial Fibrillation: A Pathophysiological Perspective and Review
    Jacob, Sony
    Ali, Omaima A.
    Pidlaoan, Victoria
    Badheka, Apurva O.
    Kerin, Nicholas Z.
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (03) : 241 - 260
  • [12] LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449
  • [13] Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach The Euro Heart Survey on Atrial Fibrillation
    Lip, Gregory Y. H.
    Nieuwlaat, Robby
    Pisters, Ron
    Lane, Deirdre A.
    Crijns, Harry J. G. M.
    [J]. CHEST, 2010, 137 (02) : 263 - 272
  • [14] A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure
    Mamas, Mamas A.
    Caldwell, Jane C.
    Chacko, Sanoj
    Garratt, Clifford J.
    Fath-Ordoubadi, Farzin
    Neyses, Ludwig
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (07) : 676 - 683
  • [15] Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure
    McDermott, MM
    Feinglass, J
    Lee, PI
    Mehta, S
    Schmitt, B
    Lefevre, F
    Gheorghiade, M
    [J]. AMERICAN HEART JOURNAL, 1997, 134 (04) : 728 - 736
  • [16] Tissue Doppler-derived index of left ventricular filling pressure, E/E′, predicts survival of patients with nonvalvular atrial fibrillation
    Okura, H.
    Takada, Y.
    Kubo, T.
    Iwata, K.
    Mizoguchi, S.
    Taguchi, H.
    Toda, I.
    Yoshikawa, J.
    Yoshida, K.
    [J]. HEART, 2006, 92 (09) : 1248 - 1252
  • [17] Are transthoracic echocardlographic parameters associated with atrial fibrillation recurrence or stroke? - Results from the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study
    Olshansky, B
    Heller, EN
    Mitchell, LB
    Chandler, M
    Slater, W
    Green, M
    Brodsky, M
    Barrell, P
    Greene, HL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (12) : 2026 - 2033
  • [18] Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction - Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity (CHARM) program
    Olsson, Lars G.
    Swedberg, Karl
    Ducharme, Anique
    Granger, Christopher B.
    Michelson, Eric L.
    McMurray, John J. V.
    Puu, Margareta
    Yusuf, Salim
    Pfeffer, Marc A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) : 1997 - 2004
  • [19] Atrial fibrillation in heart failure: High mortality risk even if ventricular function is preserved
    Parkash, R
    Maisel, WH
    Toca, FM
    Stevenson, WG
    [J]. AMERICAN HEART JOURNAL, 2005, 150 (04) : 701 - 706
  • [20] Parkash R, 2007, J AM COLL CARDIOL, V49, P376, DOI 10.1016/j.jacc.2006.10.035